X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with WYETH LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs WYETH LTD - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

WYETH LTD 
   Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA WYETH LTD GSK PHARMA/
WYETH LTD
 
P/E (TTM) x 68.1 27.7 245.8% View Chart
P/BV x 13.7 5.3 256.4% View Chart
Dividend Yield % 1.1 1.3 82.5%  

Financials

 GSK PHARMA   WYETH LTD
EQUITY SHARE DATA
    GSK PHARMA
Mar-18
WYETH LTD
Mar-13
GSK PHARMA/
WYETH LTD
5-Yr Chart
Click to enlarge
High Rs2,7601,044 264.3%   
Low Rs2,040818 249.4%   
Sales per share (Unadj.) Rs339.0298.6 113.5%  
Earnings per share (Unadj.) Rs41.457.2 72.4%  
Cash flow per share (Unadj.) Rs45.958.4 78.6%  
Dividends per share (Unadj.) Rs35.0017.00 205.9%  
Dividend yield (eoy) %1.51.8 79.9%  
Book value per share (Unadj.) Rs242.9249.5 97.4%  
Shares outstanding (eoy) m84.7022.72 372.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.13.1 227.0%   
Avg P/E ratio x57.916.3 356.2%  
P/CF ratio (eoy) x52.315.9 328.0%  
Price / Book Value ratio x9.93.7 264.7%  
Dividend payout %84.529.7 284.5%   
Avg Mkt Cap Rs m203,28021,157 960.8%   
No. of employees `000NA0.5 0.0%   
Total wages/salary Rs m5,234400 1,308.5%   
Avg. sales/employee Rs ThNM13,787.4-  
Avg. wages/employee Rs ThNM813.0-  
Avg. net profit/employee Rs ThNM2,643.3-  
INCOME DATA
Net Sales Rs m28,7156,783 423.3%  
Other income Rs m545353 154.7%   
Total revenues Rs m29,2607,136 410.0%   
Gross profit Rs m5,0591,617 312.8%  
Depreciation Rs m38027 1,428.6%   
Interest Rs m26 36.4%   
Profit before tax Rs m5,2221,938 269.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m178-5 -3,490.2%   
Tax Rs m1,892632 299.3%   
Profit after tax Rs m3,5081,301 269.7%  
Gross profit margin %17.623.8 73.9%  
Effective tax rate %36.232.6 111.1%   
Net profit margin %12.219.2 63.7%  
BALANCE SHEET DATA
Current assets Rs m21,8156,984 312.4%   
Current liabilities Rs m15,9992,056 778.2%   
Net working cap to sales %20.372.6 27.9%  
Current ratio x1.43.4 40.1%  
Inventory Days Days6499 64.1%  
Debtors Days Days1924 78.1%  
Net fixed assets Rs m12,475244 5,106.4%   
Share capital Rs m847227 372.8%   
"Free" reserves Rs m19,7265,441 362.6%   
Net worth Rs m20,5735,668 363.0%   
Long term debt Rs m625 24.0%   
Total assets Rs m39,4757,901 499.6%  
Interest coverage x2,612.0353.3 739.3%   
Debt to equity ratio x00 6.6%  
Sales to assets ratio x0.70.9 84.7%   
Return on assets %8.916.5 53.8%  
Return on equity %17.122.9 74.3%  
Return on capital %26.234.0 77.1%  
Exports to sales %00.2 0.0%   
Imports to sales %036.3 0.0%   
Exports (fob) Rs mNA15 0.0%   
Imports (cif) Rs mNA2,465 0.0%   
Fx inflow Rs m56415 3,710.5%   
Fx outflow Rs m7,4292,677 277.5%   
Net fx Rs m-6,865-2,662 257.9%   
CASH FLOW
From Operations Rs m4,728923 512.1%  
From Investments Rs m-1,042317 -328.8%  
From Financial Activity Rs m-3,066-481 637.5%  
Net Cashflow Rs m620759 81.6%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 50.7 51.1 99.2%  
Indian inst/Mut Fund % 10.2 11.3 90.3%  
FIIs % 23.8 7.2 330.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 30.4 50.7%  
Shareholders   102,036 21,978 464.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   J.B.CHEMICALS  SUVEN LIFE  STERLING BIOTECH  CADILA HEALTHCARE  VENUS REMEDIES  

Compare GSK PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Close at Record Highs; Healthcare and Power Stocks Witness Buying(Closing)

Indian share markets continued to trade on a flat during closing hours of trade and ended the day marginally higher to close at fresh record high levels.

Related Views on News

GSK PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 235.3% (Quarterly Result Update)

Jul 26, 2018 | Updated on Jul 26, 2018

For the quarter ended June 2018, GSK PHARMA has posted a net profit of Rs 886 m (up 235.3% YoY). Sales on the other hand came in at Rs 7 bn (up 21.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.4% (Quarterly Result Update)

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 6.4% YoY). Sales on the other hand came in at Rs 7 bn (down 4.5% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Only on WhatsApp, a Weaker Rupee Means a Weaker India(Vivek Kaul's Diary)

Aug 16, 2018

While dollar crossing Rs 70 will have its repercussions, the world isn't exactly coming to an end.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Aug 21, 2018 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE GSK PHARMA WITH

MARKET STATS